The DOI matches its Crossref record.
Anti-CD40 Ligand Antibody Treatment of SNF1 Mice with Established Nephritis: Preservation of Kidney Function
Open accessAbstract
Prior studies have demonstrated that treatment of young, prenephritic lupus-prone mice with Ab directed against CD40 ligand (CD40L) prolongs survival and decreases the incidence of severe nephritis. In this report, we show that for (SWR × NZB)F1 (SNF1) animals with established lupus nephritis, long-term treatment with anti-CD40L beginning at either 5.5 or 7 mo of age prolonged survival and decreased the incidence of severe nephritis. “Older” mice were chosen for these studies to more closely resemble the clinical presentation of patients with established renal disease. We show that age at the start of treatment, which typically correlates with severity of disease, is an important factor when determining an efficacious therapeutic protocol since animals that began treatment at 7 mo of age required a more aggressive treatment protocol than animals at 5.5 mo of age. Remarkably, several anti-CD40L-treated animals beginning treatment at age 5.5 mo demonstrated a decline in proteinuria, as opposed to increasing proteinuria levels seen in hamster IgG (HIg)-treated controls, and histologic examination of kidneys from anti-CD40L-treated mice revealed dramatically diminished inflammation, sclerosis/fibrosis, and vasculitis, in marked contrast to the massive inflammation and kidney destruction observed in control animals that received hamster IgG. Spleens from anti-CD40L-treated mice also exhibited markedly reduced inflammation and fibrosis compared with controls. Together, these results show that treatment of older, nephritic SNF1 animals with long-term anti-CD40L immunotherapy significantly prolongs survival, reduces the severity of nephritis, and diminishes associated inflammation, vasculitis, and fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations
Mackay, F., Woodcock, S. A., Lawton, P., Ambrose, C., Baetscher, M., Schneider, P., Tschopp, J., & Browning, J. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.11.1697 · Cited by 1,480
van Kooten, C., & Banchereau, J. (2000) · Journal of Leukocyte Biology · doi:10.1002/jlb.67.1.2 · Cited by 1,404
BAFF and APRIL: A Tutorial on B Cell Survival
Mackay, F., Schneider, P., Rennert, P., & Browning, J. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141152 · Cited by 1,007
Boumpas, D. T., Furie, R., Manzi, S., Illei, G. G., Wallace, D. J., Balow, J. E., Vaishnaw, A., & on behalf of the BG9588 Lupus Nephritis Trial Group (2003) · Arthritis & Rheumatism · doi:10.1002/art.10856 · Cited by 618
Kenyon, N. S., Chatzipetrou, M., Masetti, M., Ranuncoli, A., Oliveira, M., Wagner, J. L., Kirk, A. D., Harlan, D. M., Burkly, L. C., & Ricordi, C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.8132 · Cited by 415
Metadata
- Authors
- Kalled, S. L., Cutler, A. H., Datta, S. K., & Thomas, D. W.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-03-01
- Volume
- 160
- Issue
- 5
- Pages
- 2158-2165
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1675026965
- Cited by
- 199
- References
- 0
- FWCI
- 12.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-CD40 Ligand Antibody Treatment of SNF1 Mice with Established Nephritis: Preservation of Kidney Function. https://app.cochat.ai/papers/10.4049/jimmunol.160.5.2158
- The paper
- Kalled, S. L., Cutler, A. H., Datta, S. K., & Thomas, D. W. (1998). Anti-CD40 Ligand Antibody Treatment of SNF1 Mice with Established Nephritis: Preservation of Kidney Function. The Journal of Immunology. https://doi.org/10.4049/jimmunol.160.5.2158
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.